Alliances

Found 54,227 articles

• Tavros Therapeutics and OpenBench Expand Strategic Collaboration for Small Molecule Drug Discovery

  4/27/2023

  Tavros Therapeutics, Inc. and OpenBench, Inc. today announced the companies have entered into a collaboration agreement to discover small molecule modulators of up to five oncology targets across an initial 18-month term.

• Twist Bioscience and Aster Insights Partner on Launch of Next Generation Oncology Panel for Cancer Research

  4/27/2023

  Twist Bioscience Corporation and Aster Insights today announced the availability of the AsterExome panel, which can simultaneously enable whole exome sequencing (WES) with additional coverage for target regions known to contain 620 genes associated with cancer.

• Zura Bio Announces $80 Million Financing and the Licensing of Tibulizumab (ZB-106), a Potential First-in-Class anti-IL-17 and anti-BAFF Dual Antagonist for Autoimmune Diseases

  4/27/2023

  Zura Bio Limited today announced the license from Eli Lilly and Company (“Lilly”) of tibulizumab, a potential first-in-class, anti-IL-17 and anti-BAFF dual antagonist.

• Ubie signs a broad collaboration agreement with Takeda Pharmaceuticals to promote digital transformation

  4/27/2023

  Ubie Inc. has signed a comprehensive collaboration agreement with Takeda Pharmaceutical Co., Ltd. to promote digital transformation, which aims to guide people to appropriate medical care for rare diseases and gastrointestinal diseases.

• Hansa Biopharma and Genethon announce collaboration to develop imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies

  4/27/2023

  Hansa Biopharma AB, "Hansa", (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, and Genethon, a pioneer and a leader in gene therapy research and development for rare genetic diseases, today announced they have entered a research and development collaboration.

• ChromaCode Announces Partnership with MedGenome to Bring HDPCR-based Diagnostics to India and the Middle East

  4/27/2023

  ChromaCode, Inc., a genomics multiplexing platform company developing accessible and affordable solutions for laboratories, patients and physicians, announced today a partnership with MedGenome, to bring its innovative High Definition PCR (HDPCR™) multiplexing technology to India and the Middle East.

• Healint announces a collaboration with Saitama Medical University Hospital, Japan, to verify AI diagnosis of Migraine

  4/27/2023

  Saitama Medical University Hospital and Healint launched one of the world's first clinical studies titled "Verification of Headache AI diagnosis by using Electronic Headache Diary in Telemedicine".

• Generate:Biomedicines and MD Anderson Enter Co-Development and Commercialization Agreement to Accelerate Novel Protein Therapeutics for Oncology Using Generative AI

  4/27/2023

  Generate:Biomedicines and The University of Texas MD Anderson Cancer Center today announced a strategic collaboration to jointly discover and co-develop protein therapeutics for up to five oncology targets in advanced cancers, including small-cell and non-small-cell lung cancer.

• Enzolytics Inc. Continues Progress with Business Combination; Biogenysis Announces Team and Plans for Success

  4/27/2023

  Enzolytics, Inc. (OTC announces its continuing progress with the recently announced business combination between Enzolytics' operating subsidiaries, Biogenysis and Virogentics, and Sagaliam Acquisition Corp.

• BioMed X Launches XSeed Labs in the US with Boehringer Ingelheim - a New Model for Building an External Innovation Ecosystem on an Industry Campus

  4/27/2023

  BioMed X announced the expansion of its collaboration with Boehringer Ingelheim with the launch of a new model for biomedical research: XSeed Labs.

• Rockwell Medical's Partner Drogsan Pharmaceuticals Submits Marketing Authorization Application in Turkey for Triferic AVNU

  4/27/2023

  Rockwell Medical, Inc. announced that its international partner, Drogsan Pharmaceuticals, submitted a Marketing Authorization application and GMP application for Triferic® AVNU to the Turkish Medicines and Medical Devices Agency, for which Drogsan received priority status and high priority status, respectively.

• The Life Science Business of Merck KGaA, Darmstadt, Germany Signature Partnerships Advance Access to Science Education

  4/27/2023

  Building on its focus to spark curiosity in the next generation of scientists and accelerate global access to science, MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, announces eight new and expanded Signature Partnerships for 2023-2025.

• Sunovion and Otsuka Initiate Clinical Development of Ulotaront for the Treatment of Generalized Anxiety Disorder

  4/26/2023

  Sunovion Pharmaceuticals Inc. (Sunovion) and Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka) today announced that the first patient has been randomized in a Phase 2/3 clinical study evaluating ulotaront, a trace amine-associated receptor 1 (TAAR1) agonist with 5-HT 1A agonist activity, for the treatment of generalized anxiety disorder (GAD).

• Endo Announces Agreement with Slayback Pharma to Distribute Prevduo™ (neostigmine methylsulfate and glycopyrrolate injection)

  4/26/2023

  Endo International plc (OTC: ENDPQ) announced today that its subsidiaries Endo Ventures Limited and Par Pharmaceutical, Inc. (collectively "Endo") have executed an agreement with Slayback Pharma LLC to distribute Slayback's Prevduo ™ (neostigmine methylsulfate and glycopyrrolate injection) pre-filled syringe on an exclusive basis in the U.S.

• Bristol Myers Squibb Strengthens Cell Therapy Capabilities by Adding New U.S. Manufacturing Facility for Viral Vector Production

  4/26/2023

  Bristol Myers Squibb (NYSE: BMY) today announced expansion of its global cell therapy manufacturing network to enable in-house viral vector production through a U.S.-based manufacturing facility and its operations in Libertyville, Illinois, following the company’s execution of an agreement with Novartis.

• Mainz Biomed Announces Partnership with the Instituto de Microecologia to Expand ColoAlert® Commercialization in Spain and Portugal

  4/26/2023

  Mainz Biomed NV, a molecular genetics diagnostic company specializing in the early detection of cancer, announced that it has added the Instituto de Microecologia in Madrid to its growing network of lab partners across Europe and in select international markets.

• HTG Provides Update on Drug Discovery Partnering Initiative

  4/25/2023

  HTG Molecular Diagnostics, Inc., a platform-based life science tools and drug discovery company, provided an update on partnering discussions for its drug discovery business unit.

• MiNA Therapeutics Enters Research Collaboration with BioMarin Pharmaceutical to Advance RNAa Platform Research in Rare Genetic Diseases

  4/25/2023

  MiNA Therapeutics today announced a multi-target research collaboration and option licensing agreement with BioMarin Pharmaceutical Inc.

• Indica Labs and Lunit Announce a Strategic Alliance for Seamless Integrated Digital Pathology AI Workflows

  4/25/2023

  Indica Labs and Lunit, a leading medical AI software platform company focused on cancer biomarkers announced an agreement to provide a fully interoperable solution between Indica Labs' HALO AP® image management software platform and Lunit's suite of AI pathology products.

• Juno Pharmaceuticals Partners With Rosemont Pharmaceuticals as Exclusive Canadian Distributor to Offer Previously Inaccessible Medicines

  4/25/2023

  Juno Pharmaceuticals Canada announced its partnership with U.K. based developer, manufacturer and global supplier of novel, Rx, oral liquid medicines, Rosemont Pharmaceuticals (“Rosemont”), as its exclusive Canadian distributor.